Cristina Gasparetto, MD Duke University Interview Date: February 17,  2017 

 Allogeneic stem cell transplant can be selectively and successfully used for young and high-risk myeloma patients. Allo transplant is considered the "first" ever immunotherapy. It essentially transplants a new immune system from a donor to the myeloma patient, replacing their own. There are several types of allo transplant: 1) myeloablative or the use of high-dose chemotherapy and non-myeloablative which is considered a "mini" allo transplant. Dr. Gasparetto explains the different types of allo transplant, their pros and cons of each type. She notes that because allo transplant patients can experience graft vs. host disease, that the use of allo transplant should optimally be used in the clinical trial setting. She describes her allo clinical trial for newly diagnosed patients that uses an allo transplant with an oral proteasome inhibitor as maintenance therapy and explains the rationale. Allo transplant can be used in both the newly diagnosed setting and in the relapsed or "salvage" setting. She notes that it is most effective in this setting if the myeloma is well under control. For patients consider an allogeneic transplant, this is a very informative show. 

Thanks to our episode sponsor